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Aims Implantable loop recorders (ILRs) with speciﬁc atrial ﬁbrillation (AF) detection algorithms (ILR-AF) have been devel-
oped for continuous AF monitoring. We sought to analyse the clinical value of a new AF monitoring device and to
compare it to serial 7-day Holter.
Methods
and results
Sixty-four consecutive patients suffering from paroxysmal AF were included in this prospective analysis and received
an ILR-AF. Manual electrogram analysis was performed for each automatically detected episode and each was cate-
gorized into one of three possible diagnoses: ‘no AF’, ‘deﬁnite AF’, and ‘possible AF’ (non-diagnostic). Analysis was
performed separately before and after a software upgrade that was introduced during the course of the study. A
subgroup of patients (51 of 64) underwent AF catheter ablation with subsequent serial 7-day Holter in comparison
with the ILR-AF. A total of 333 interrogations were performed (203 before and 130 after software upgrade). The
number of patients with AF misdetection was signiﬁcantly reduced from 72 to 44% following the software
upgrade (P ¼ 0.001). The number of patients with non-diagnostic interrogations went from 38 to 16%
(P ¼ 0.001). Compared with serial 7-day Holter, the ILR-AF had a tendency to detect a higher number of patients
with AF recurrences (31 vs. 24%; P ¼ 0.125).
Conclusions The rate of AF detection on ILR-AF may be higher compared with standard AF monitoring. However, false-positive
AF recordings hamper the clinical value. Developements in device technology and device handling are necessary to
minimize non-diagnostic interrogations.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Atrial ﬁbrillation (AF) is the most commonly diagnosed arrhythmia,
resulting in signiﬁcant morbidity and cost to the healthcare
system.
1 Asymptomatic or silent arrhythmia is a frequent condition
in patients suffering from AF.
1,2 It is observed in a substantial
number of patients suffering from cryptogenic stroke.
3 Due to
the inability to reliably detect asymptomatic AF recurrences,
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Europace (2011) 13, 480–485
doi:10.1093/europace/euq511clinical and scientiﬁc uncertainty remains for fundamental treat-
ment decisions such as rate vs. rhythm control or the need for
oral anticoagulation.
4
Several methods have been described to improve rhythm moni-
toring in AF patients.
3,5–7 In general, these data have shown an
increased AF detection rate with longer monitoring durations.
6,8
However, even with serial 7-day Holter electrocardiograms
(ECGs) or daily plus symptom-activated transtelephonic ECG
monitoring, it is estimated to detect only  70% of all recurring
AF episodes.
9
To provide continuous AF rhythm monitoring, implantable lead-
less loop recorders with speciﬁc AF detection algorithms (ILR-AF)
have been developed. In patients with paroxysmal AF, the XPECT
trial evaluated the detection performance of an ILR-AF (Reveal
XT) against a specialized surface ECG Holter device over a
short monitoring period of 46 h. The results of the study indicated
a high sensitivity of 96.1% for detecting AF. However, speciﬁcity
(85.4%) was limited by falsely stored AF episodes in 15% of the
patients.
10
The purpose of this study was to analyse the performance of the
implantable continuous AF detection device in a clinical setting
before and after introduction of a software upgrade with monitor-
ing periods covering several months and to compare it with stan-
dard monitoring based on serial 7-day Holter.
Methods
Patient population and study design
Between September 2007 and February 2008, 64 consecutive patients
(69% male, mean age 60+9 years) suffering from paroxysmal AF were
included into this prospective analysis. Thirteen patients (20%) suffered
from lone AF and 45 (70%) from arterial hypertension with a mean left
atrial diameter of 43+7 mm and a left ventricular ejection fraction of
61+9%.
All of the patients had received an ILR-AF (Medtronic Reveal XT
TM
model 9529) during the course of the XPECT study.
10 After termin-
ation of the XPECT study, the patients were included into routine clini-
cal follow-up. Our data represent an analysis of the ILR-AF
performance during a longer and clinically relevant AF monitoring
period of an average of 57 days (75% range: 23–98 days).
Due to a high amount of AF misdetection, mostly caused by oversen-
sing of myopotentials and artefacts, a software update (see below) was
introduced in June 2008 during the course of the study. Interrogations
were analysed with the use of manual EGM analysis (see below) and
results before and after software update were compared.
During the course of the study, a subgroup of patients (n ¼ 51, 79%)
underwent circumferential pulmonary vein isolation and was followed
with serial (post-ablation, after 3 months, after 6 months, after
12 months) 7-day Holter recordings (Lifecard CF, DelmarReynolds
Medical Inc, Irvine, CA, USA) in addition to the ILR-AF interrogations.
The physician performing the Holter analysis was blinded with regard
to patient name, date of ablation, and the patient’s symptom log. Based
on the ILR-AF detection algorithm (see below), AF recurrence was
deﬁned as a documented AF episode lasting longer than 2 min to allow
for comparison between ILR-AF and 7-day Holter monitoring results.
Implant procedure
The ILR-AF was implanted in a left parasternal position. Optimal
orientation of the device axis was determined prior to implantation.
For that, the vector check tool was used (Medtronic, Minneapolis,
MN, USA), which allows testing for the highest R-wave amplitude
obtained from a single lead recording in different locations/orientations
on the body surface. During implantation, the device was pushed into
the subcutaneous tissue without prior pocket preparation, in order to
assure close tissue-device contact and to prevent mobility of the
device within the pocket. The device was ﬁxated within the pocket.
Software and device description
The AF detection algorithm operates through an assessment on the
regularity of RR intervals (Lorenz plot) within a 2 min time window.
11
Once AF is diagnosed, it is stored as a sustained AF episode within
the automatic episode counter, showing date and time of occurrence
as well as episode length. After detection, the device is capable of
storing 2 min of each AF episode as electrogram (EGM) with a total
storage capacity of 49.5 min. Once storage is exhausted, older EGMs
are overwritten with newer ones. However, the automatic episode
counter is not overwritten until the next interrogation.
The mentioned upgraded software aims at a reduction of noise-
induced false-positive AF episodes by reducing the noise rejection
threshold from 60 to 5 s. In this way, episodes containing .5s o f
noise in a 2 min window are not considered for classiﬁcation.
As additional device tools, an external assistant box (Medtronic
Reveal XT
TM patient assistant model 9539) allows patients to tag
and store symptomatic episodes by activating a recording button; fur-
thermore, the patient can check whether EGM storage capacity is
exhausted by activating an interrogation button. Nevertheless, this
alarm was not activated in our patients.
In addition to AF detection, the device also detects and classiﬁes
other types of arrhythmias, e.g. asystole, bradycardia, and tachycardia.
However, storage of non-AF episodes was disabled unless individual
patient history warranted detection of other arrhythmias. In these
cases, storage of those episodes was permitted; however, only AF epi-
sodes were analysed.
Interrogations and follow-up
All patients were integrated in the routine follow-up within the pace-
maker/implantable cardiac deﬁbrillator clinic with quarterly visits and
additional visits upon request. Interrogation of the ILR-AF is similar
to pacemaker interrogations and requires the Medtronic programmer
(Medtronic CareLink programmer model 2090, software model
SW007). The standard setting for R-wave sensing was 0.05 mV.
Depending on the occurrence of under- or oversensing, it was
adjusted during follow-up accordingly.
From a clinical perspective, each interrogation was classiﬁed accord-
ing to the diagnosis derived from automatic AF detection and manual
analysis of all stored EGMs (Figure 1A and B). Automatically stored AF
episodes were judged by an experienced physician as adequate if there
was an irregular RR pattern in the absence of P-waves throughout the
EGM recording. With that approach, an interrogation could lead to the
diagnosis: (i) no AF; (ii) deﬁnite AF; (iii) possible AF (non-diagnostic
interrogation) (Table 1). The diagnosis of ‘no AF’ was made in cases
where the automatic AF counter was zero.
Statistics
The data were tested for normal (Gaussian) distribution using
Kolmogoroff–Smirnov test. Normally distributed continuous variables
are presented as mean+standard deviation (SD). In case of a
non-Gaussian distribution, median and quartiles are given. Categorical
variables are expressed as number and percentage of patients and
interrogations, respectively.
Implantable device for AF monitoring 481Differences between continuous normally distributed data
before and after the software upgrade were tested for statistical
signiﬁcance using the paired t-test. In case of continuous data with a
non-Gaussian distribution the Wilcoxon test was used. Differences
between categorical data before and after the software upgrade as
well as the rate of AF detection on ILR-AF and on 7-day Holter
were tested for statistical signiﬁcance using the McNemar test.
All analyses were performed using SPSS for Windows, Release 12.0.
A P-value of ,0.05 was considered statistically signiﬁcant.
Results
No complications occurred during or after implantation, no per-
sistent discomfort was reported and no explanations of the
device were necessary during follow-up. Among the 64 patients,
a total of 333 interrogations were performed. Of those, 203 inter-
rogations occurred before and 130 interrogations occurred after
the software upgrade. Results of manual interrogation analysis
are displayed separately for interrogations before and after the
software upgrade in Figure 2A and B.
Details on distribution of interrogations, number of AF episodes,
length of follow-up period, mean R-wave amplitude, length of clini-
cal follow-up, and amount of storage overﬂow are summarized in
Table 2.
Non-diagnostic interrogations
Interrogations with automatically stored AF episodes containing
only EGMs with sinus rhythm and artefacts leading to AF
Figure 1 (A) Device stored electrogram with correctly classiﬁed atrial ﬁbrillation. (B) Device stored electrogram with misclassiﬁed AF (red
arrows) due to myopotentials (upper panel) and PAC (lower panel).
...............................................................................................................................................................................
Table 1 Deﬁnition of clinical diagnosis of interrogations based on manual electrogram analysis
Automatic episode counter no AF episodes limited AF episodes
(EGM for all episodes)
multiple AF episodes (EGM not for all
episodes)
Manual EGM analysis – Only SR With AF With AF Only SR
Diagnosis No AF No AF Deﬁnite AF Deﬁnite AF Possible AF (non-diagnostic)
C. Eitel et al. 482misdetection could be found in 22% of interrogations prior and
10% after the software upgrade, respectively (Figure 2A and B).
For these interrogations, however, it is unclear whether AF was
present among the remaining automatically stored AF episodes
without available EGM.
Causes of atrial ﬁbrillation misdetection
Before and after software upgrade, reasons for AF misdetection
were the occurrence of myopotentials/noise in 70/203 interroga-
tions (35%) vs. 28/130 (22%), T-wave oversensing in 3/203
(1.5%) vs. 1/130 (1%), frequent premature ventricular or atrial
complexes (PVCs/PACs) in 28/203 (15%) vs. 26/130 (20%), as
well as R-wave undersensing in 9/203 (4%) vs. 7/130 (5%),
respectively.
Individual patient analysis before and
after software upgrade
The length of follow-up intervals between consecutive interroga-
tions did not vary before and after software upgrade [49 (23;
98) vs. 68 (25; 98) days; P ¼ 0.276]. However, the length of total
clinical follow-up before and after software upgrade was signiﬁ-
cantly longer prior software upgrade (193 + 85 days prior
upgrade vs. 141 + 54 after upgrade; P , 0.001).
Interrogations before update in 64 patients
n = 203
no AF episodes
n = 32
limited AF episodes,
EGM for all episodes
n = 70
multiple AF episodes,
EGM not for all episodes
n = 101
only SR 
with artefacts
n = 23 (11%)
AF, and SR 
with artefacts
n = 47 (23%)
only SR
no artefacts
n = 32 (16%)
AF, and SR 
with artefacts
n = 57 (28%)
only SR 
with artefacts
n = 44 (22%)
No AF Definite 
AF
No AF Definite 
AF
Possible 
AF
no AF episodes
n = 40
limited AF episodes,
EGM for all episodes
n = 48
multiple AF episodes,
EGM not for all episodes
n = 42
only SR 
with artefacts
n = 24 (19%)
AF, and SR 
with artefacts
n = 24 (19%)
only SR
no artefacts
n = 40 (31%)
AF, and SR 
with artefacts 
n = 29 (22%)
only SR 
with artefacts
n = 13 (10%)
No AF Definite 
AF
No AF Definite 
AF
Possible 
AF
Interrogations after update in 64 patients
n = 130
Automatic 
episode 
counter
Automatic 
episode 
counter
Manual 
EGM
analysis
Manual 
EGM
analysis
Diagnosis
Diagnosis
A
B
Figure 2 (A and B) Clinical classiﬁcation of interrogations before and after software upgrade.
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Table 2 Characteristics of interrogations before and
after software upgrade
Before
software
upgrade
After
software
upgrade
P-value
Total number of
interrogations, n
203 130
Number of interrogations
per patient
a
2.6 + 1.8 1.9 + 1.3 ,0.001
Number of AF episodes, n
b 27 (3; 125) 5 (1; 20) ,0.001
R-wave amplitude, mV
b 0.7 (0.4; 0.8) 0.7 (0.5; 0.9) 0.166
cMonitoring period, days
b 49 (23; 98) 68 (25; 98) 0.276
dLength of clinical
follow-up
a
193 + 85 141 + 54 ,0.001
eInterrogations with
storage overﬂow, n (%)
101 (50%) 42 (32%)
aData given as mean and standard deviation.
bData given as median and quartiles.
cMonitoring interval between two subsequent ILR-AF interrogations.
dLength of clinical follow-up was deﬁned as total monitoring time before and after
software upgrade.
eInterrogations with storage overﬂow were deﬁned as interrogations including
automatic episodes without available EGM.
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reduced the number of patients with any misdetection of AF
[46/64 (72%) vs. 28/64 (44%); P ¼ 0.001]. This reduction was
mainly attributable to a signiﬁcantly lower number of patients
having AF misdetection due to myopotentials or noise [32/64
(50%) vs. 15/64 (23%); P , 0.001]. On the other hand, the occur-
rence of R-wave undersensing [6/64 (9%) vs. 5/64 (8%); P ¼ 1.0],
T-wave oversensing [3/64 (5%) vs. 1/64 (2%); P ¼ 0.625], misde-
tection of PVC [3/64 (5%) vs. 1/64 (2%), P ¼ 0.625], and PAC
[20/64 (31%) vs. 14/64 (22%), P ¼ 0.238] were not signiﬁcantly
improved with the introduction of the software upgrade.
The number of patients with clinically non-diagnostic interroga-
tions was signiﬁcantly reduced [24/64 (38%) vs. 10/64 (16%); P ¼
0.001] (Figure 3). A detailed evaluation of the 10 patients with non-
diagnostic interrogations despite the software upgrade revealed
the following reasons of frequent AF misdetection: myopotential
oversensing (n ¼ 7), frequent PACs (n ¼ 5), R-wave undersensing
(n ¼ 3). Simultaneous over- and undersensing occurred in three
patients, posing a challenge for the adjustment of R-wave sensing.
Atrial ﬁbrillation detection on
implantable loop recorder compared
with 7-day Holter
Outof64patients,51(80%)underwentcircumferentialPVisolation.
With serial 7-day Holter monitoring, 12 of 51 (24%) patients had
documented episodes of AF recurrences. In all of these patients,
AFwascorrectlyidentiﬁedbytheILR-AF.Infouradditionalpatients,
AFrecurrencesweredetectedbytheILR-AFwhichwasnotseenon
7-dayHolter.Therefore,therateofdocumentedAFrecurrencehad
a tendency to be higher on ILR-AF, but failed to reach statistical sig-
niﬁcance [16/51 (31%) vs. 12/51 (24%); P ¼ 0.125].
Discussion
Main ﬁndings
This is the ﬁrst study to evaluate the implantable continuous AF
detection device in long-term clinical routine based on a manual
analysis of automatically stored AF episodes. Compared with high-
quality standard measures of AF monitoring such as serial 7-day
Holter, the device increased the total number of patients with
AF detection. However, we also found a high rate of false-positive
AF recordings mainly caused by oversensing of myopotentials and
noise. Together with an only limited EGM storage capacity that led
to non-diagnostic interrogations in 38% of the patients. Following
software upgrade, the speciﬁcity of the device improved with
non-diagnostic interrogations in 16% of the patients.
Role of implantable loop recorders
in atrial ﬁbrillation detection
Implantable loop recorders have become an important diagnostic
tool for the patient with unexplained syncope and are well estab-
lished for this purpose.
12 In how far this monitoring strategy is
useful for rhythm follow-up in patients with AF remains to be
evaluated.
During an initial validation study, a high sensitivity of 96.1% for
detecting AF was found, while speciﬁcity was limited by falsely
stored AF episodes in 15% of the patients.
10
Recently, a second study has compared the AF detection rate
obtained from ILR-AF against three-monthly 24-h Holter in
patients after surgical ablation of AF over a 1-year follow-up. Exclu-
sive usage of automatically detected AF episodes obtained with the
old detection algorithm prior to the software upgrade together
with the lack of any information on manual EGM analysis and the
problem of AF misdetection limits the understanding on the true
value of the ILR-AF for long-term continuous AF monitoring in
this study.
13
Our study is the ﬁrst one using the ILR-AF as long-term continu-
ous AF monitoring device in clinical routine and validating its diag-
nostic accuracy according to manual analysis of all automatically
stored AF episodes. Some key ﬁndings need to be emphasized.
The AF detection rate of the device tended to be higher compared
with standard serial 7-day Holter ECG recordings. However, due
to oversensing of myopotentials and subsequent AF misdetection,
speciﬁcity is lacking. Similar results have been shown for other
device-based rhythm monitoring, e.g. pacemaker or implantable
deﬁbrillators. In prospective randomized trials, the relative
portion of misclassiﬁed AF episodes by an implanted dual-chamber
pacemaker is  26%.
14
Oversensing of myopotentials, mostly from the pectoral muscle,
was found to be the leading cause for false-positive AF annotation
in our study. In order to minimize myopotential detection, a new
and improved software algorithm was released during the course
of the study. Our results show that using the updated algorithm
the number of patients with non-diagnostic interrogations could
be reduced from 38 to 16%. However, considering the invasive
nature of the follow-up tool, this rate of non-diagnostic data sets
has to be improved.
Measurements to reduce non-diagnostic
interrogations
Besides further software developments, several measures can be
discussed to reduce the number of non-diagnostic interrogations.
To recognize false-positive AF episodes, all automatically detected
0
10
20
30
40
50
60
No AF Definite AF Possible AF ‘non-
diagnostic’
Patients before software upgrade
Patients after software upgrade
P<0.001
n =       64     64                  64     64 64     64
P<0.001
P=1.0
N
u
m
b
e
r
 
o
f
 
p
a
t
i
e
n
t
s
 
(
%
)
Figure 3 Clinical classiﬁcation of patients before and after the
software upgrade.
C. Eitel et al. 484episodes need to be conﬁrmed on manual EGM analysis. There-
fore, it is necessary to prevent EGM storage overcrowding. That
can be achieved with two methods. First, the patient assistant
box has the ability to indicate full EGM storage through an alarm
signal which should initiate a visit to the device clinic in order to
retrieve and analyse all available EGMs. That in return would
lead to individualized follow-up intervals. Secondly, remote moni-
toring techniques like the CareLink network allow patient initiated
sending of diagnostic and monitoring information from home. This
provides the possibility of regularly relieving the EGM storage and
could enhance manual EGM analysis for all automatically stored
episodes.
Prolongation of the detection period for sustained AF may be a
different way to prevent episodes of AF misdetection, because
false-positive AF episodes are rather short. Programming options
of the ILR-AF include detection periods for sustained AF of
6 min and more. Clearly, shorter AF episodes will then be unrec-
ognized. The clinical and scientiﬁc impact of such a change in deﬁ-
nition of sustained AF remains to be evaluated.
The impact of the above-discussed measures on the accuracy of
the ILR-AF in the clinical setting of continuous AF monitoring has
to be assessed within further studies.
Study limitations
This study is an observational study reporting the ﬁrst experiences
with an implantable leadless continuous monitoring device for AF
in a clinical setting. It needs to be emphasized, however, that
patients’ follow-up intervals were routinely integrated into the
pacemaker clinic, i.e. follow-up intervals were not individualized
for each patient since they were not based on patients’ self assess-
ment of remaining EGM storage capacity with the patient assistant.
The CareLink system facilitating remote device interrogation with
the aim of reducing storage overﬂow was also not available in our
patients. Nevertheless, the importance of manual episode analysis
and the problem of storage exhaustion due to false-positive AF
episodes ﬁrst arose from our experience with the device.
Variations in length of clinical follow-up and in frequencies of
interrogations before and after software upgrade as well as per-
formance of AF ablation during the course of the study might
have impacted the results of the study.
Although the number of non-diagnostic interrogations was
reduced after software upgrade, the lack of a gold standard for
continuous AF monitoring over such extended follow-up periods
prevents a conclusive assessment of diagnostic accuracy with
respect to positive and negative predictive values. Therefore,
decreasing the number or proportion of stored episodes with
noise does not necessarily imply an actual improvement in AF
detection accuracy from the users’ perspective.
Although we could show that this device is valid, its relevance
for clinical decision-making in patients with AF remains to be
seen. As this device is mainly used for AF detection, other atrial
and ventricular arrhythmias have not been evaluated in this study.
Conclusion
The ILR-AF is a ﬁrst and promising tool for continuous AF
monitoring. To incorporate this device into routine patient care,
developments in device technology and device handling are
still necessary to minimize the number of non-diagnostic
interrogations.
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